RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an Outperform rating on Nurix Therapeutics (NASDAQ:NRIX) and raised the price target from $22 to $23.

April 11, 2024 | 2:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained an Outperform rating on Nurix Therapeutics and increased the price target from $22 to $23.
The upgrade in the price target by a reputable analyst like Gregory Renza suggests a positive outlook on the stock, likely due to anticipated performance improvements or positive developments within Nurix Therapeutics. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100